| Name | NL-1 |
| Description | NL-1, a mitoNEET inhibitor, exhibits antileukemic effects. |
| Cell Research | Cell Line:REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines. Concentration:10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM.Incubation Time:72 hours |
| Animal Research | Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells. Dosage:10 mg/kg.Administration:Intraperitoneal injection; daily; for 5 days |
| In vitro | NL-1 Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. |
| In vivo | NL-1 showed antileukemic activity in an in vivo mouse ALL model |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (14.9 mM), Sonication is recommended. DMSO : 250 mg/mL (745.25 mM), Sonication is recommended.
|
| Keywords | viability | NL-1 | NL1 | NL 1 | MitoNEET | MitochondrialMetabolism | Mitochondrial Metabolism | lymphoblastic | leukemia | Inhibitor | inhibit | CISD1 | B-Cell | Autophagy | antileukemic | anti-cancer | acute |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Paeonol | Naringin | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Cuproptosis Compound Library | Glycometabolism Compound Library | Reprogramming Compound Library | Mitochondrial Membrane Protein-Targeted Compound Library | Bioactive Compound Library | Autophagy Compound Library | Inhibitor Library | NO PAINS Compound Library | Mitochondria-Targeted Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |